BMX.WA Stock - BioMaxima S.A.
Unlock GoAI Insights for BMX.WA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $52.85M | $46.79M | $143.87M | $79.09M | $61.61M |
| Gross Profit | $23.26M | $20.02M | $54.23M | $28.99M | $23.85M |
| Gross Margin | 44.0% | 42.8% | 37.7% | 36.7% | 38.7% |
| Operating Income | $1.31M | $728,000 | $34.85M | $13.65M | $10.47M |
| Net Income | $535,000 | $586,000 | $28.89M | $10.24M | $7.95M |
| Net Margin | 1.0% | 1.3% | 20.1% | 13.0% | 12.9% |
| EPS | $0.13 | $0.14 | $6.68 | $2.37 | $1.93 |
BioMaxima S.A. manufactures and distributes reagents for in vitro diagnostics in Poland. Its primary products include diagnostic reagents and analyzers for clinical chemistry; rapid tests and readers for detecting infectious diseases, cancer markers, cardiac markers, and drugs of abuse; urine analysis systems; hematology analyzers and reagents; ionselective analyzers and reagents; reagents and immunological analyzers of cardiac markers; glucometers for professional use; and analyzers for gasometric tests and critical blood parameters tests. The company also provides surfaces and air controls; antibiotics discs and MIC strips; and chromogenic, dehydrated, and prepared culture media; and additives and supplements for media. It supplies its products to approximately 2,000 laboratories in Poland, as well as exports in the international markets. BioMaxima S.A. was founded in 2002 and is based in Lublin, Poland.
Visit WebsiteEarnings History & Surprises
BMX.WAEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 28, 2025 | — | $-0.07 | — | — |
Q2 2025 | May 30, 2025 | — | — | — | — |
Q1 2025 | Mar 31, 2025 | — | $0.14 | — | — |
Q4 2024 | Dec 31, 2024 | — | $0.23 | — | — |
Q3 2024 | Sep 30, 2024 | — | $-0.06 | — | — |
Q2 2024 | Jun 29, 2024 | — | $-0.10 | — | — |
Q2 2024 | May 29, 2024 | — | $0.06 | — | — |
Q4 2023 | Dec 30, 2023 | — | $0.02 | — | — |
Q4 2023 | Nov 30, 2023 | — | $-0.09 | — | — |
Q2 2023 | Jun 30, 2023 | — | $0.09 | — | — |
Q1 2023 | Mar 31, 2023 | — | $0.11 | — | — |
Q4 2022 | Dec 31, 2022 | — | $0.07 | — | — |
Q3 2022 | Sep 30, 2022 | — | $0.21 | — | — |
Q2 2022 | Jun 30, 2022 | — | $0.77 | — | — |
Q1 2022 | Mar 31, 2022 | — | $5.43 | — | — |
Q4 2021 | Dec 31, 2021 | — | $0.45 | — | — |
Q3 2021 | Sep 30, 2021 | — | $0.30 | — | — |
Q2 2021 | Jun 30, 2021 | — | $0.14 | — | — |
Q1 2021 | Mar 31, 2021 | — | $1.40 | — | — |
Q4 2020 | Dec 31, 2020 | — | $0.67 | — | — |
Latest News
Frequently Asked Questions about BMX.WA
What is BMX.WA's current stock price?
What is the analyst price target for BMX.WA?
What sector is BioMaxima S.A. in?
What is BMX.WA's market cap?
Does BMX.WA pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to BMX.WA for comparison